Assessment of Nociceptin/Orphanin FQ Peptide Receptor Occupancy After Single Oral Doses of LY2940094 as Measured by Positron Emission Tomography With the Radioligand LY2959530 in Healthy Subjects

Trial Profile

Assessment of Nociceptin/Orphanin FQ Peptide Receptor Occupancy After Single Oral Doses of LY2940094 as Measured by Positron Emission Tomography With the Radioligand LY2959530 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs BTRX 246040 (Primary)
  • Indications Depression
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Feb 2017 study is completed in 2011 and sponsor is changed after study completion,hence BlackThorn Therapeutics, Inc. is not added in association.
    • 27 Jun 2016 Results published in the Drug Metabolism and Disposition
    • 14 Dec 2014 Dose of LY2940094 is changed for every cohort as cohort 1: 100mg to 40mg, cohort 2: 2-800mg to 10mg, cohort 3: 2-800mg to 4mg, cohort 4: 2-800mg to 20mg as per ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top